Trident Drives Engagement for Singapore’s National Day Parade 2025 
HKTDC appoints Sophia CHONG as Executive Director IMPROVATE CleanTech & Renewable Energy Conference: “Countries that fail to join the cleantech revolution will pay a heavy price”
TEL AVIV, Israel, March 25, 2021 /PRNewswire/ — IMPROVATE’s CleanTech and Renewable Energy international conference…
Lumentum Receives Notice of Termination of Coherent Merger Agreement
SAN JOSE, Calif., March 25, 2021 /PRNewswire/ —Â Lumentum Holdings Inc. (“Lumentum”) today announced that Coherent,…
Global Investment Priorities in the Communication and Collaboration Space, According to Frost & Sullivan
SANTA CLARA, Calif., March 25, 2021 /PRNewswire/ — Frost & Sullivan’s recent analysis, Communications and…
Convening of the Ordinary General Meetings of Shareholders of 30 April 2021
CONVENING OF THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERSÂ OF 30 APRIL 2021 The shareholders are invited…
Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia
Topline data expected in the first half of 2021 UNIONDALE, N.Y., March 25, 2021 (GLOBE…
Santhera Launches Exchange Offer for its CHF 60 Million Convertible Bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL…
Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan
Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line Lynparza®…
LAVA Therapeutics Announces Pricing of Initial Public Offering
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics B.V. (Nasdaq:…
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) – Seraph Research Institute (SRI)…
Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing
NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or…
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally…
iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
– Initial data from Phase 1/2a trial of EOS-448 to be presented at American Association…
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021
BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or…
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
AgraFlora Provides Dial-In Information for Annual General Meeting and Business Update Presentation
VANCOUVER, British Columbia, March 24, 2021 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“AgraFlora” or…
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of…
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
Cash runway into the second half of 2023 Announced positive interim data from EQUATE study…
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time YAVNE, Israel, March…
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
– Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 – – NASH histology…